Lauren Averett Byers

Integrated Approaches for the Use of Large Datasets to Identify Rational Therapies for the Treatment of Lung Cancers

Jing Wang, Robert J. Cardnell, Lauren Averett Byers, 2019, Cancers.

Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1.

Michael Peyton, Li Shen, John N Weinstein, 2012, Cancer discovery.

The BATTLE-2 Study: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer.

Li Shen, John V Heymach, Kevin R Coombes, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Use of proteomic analysis of LKB1/AMPK/mTOR pathways to identify IGF-1R pathway upregulation with LKB1 loss or mTOR inhibition in NSCLC: Implications for targeted combinations.

John D. Minna, Kevin R. Coombes, Lixia Diao, 2012 .

Development and Validation of a Prognostic Gene-Expression Signature for Lung Adenocarcinoma

Eun Sung Park, Gordon B. Mills, Sang Bae Kim, 2012, PloS one.

CHK1 Inhibition in Small-Cell Lung Cancer Produces Single-Agent Activity in Biomarker-Defined Disease Subsets and Combination Activity with Cisplatin or Olaparib.

Pan Tong, John V Heymach, Abena B. Redwood, 2017, Cancer research.

Dynamic variations in epithelial-to-mesenchymal transition (EMT), ATM, and SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung cancer

Ying Feng, Pan Tong, Robert J. Cardnell, 2017, Oncotarget.

An Epithelial–Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance

Michael Peyton, John D. Minna, Li Shen, 2012, Clinical Cancer Research.

A Patient-Derived, Pan-Cancer EMT Signature Identifies Global Molecular Alterations and Immune Target Enrichment Following Epithelial-to-Mesenchymal Transition

Jaime Rodriguez-Canales, Pan Tong, Kevin R. Coombes, 2015, Clinical Cancer Research.